CY1114777T1 - Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη - Google Patents
Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετηInfo
- Publication number
- CY1114777T1 CY1114777T1 CY20131101171T CY131101171T CY1114777T1 CY 1114777 T1 CY1114777 T1 CY 1114777T1 CY 20131101171 T CY20131101171 T CY 20131101171T CY 131101171 T CY131101171 T CY 131101171T CY 1114777 T1 CY1114777 T1 CY 1114777T1
- Authority
- CY
- Cyprus
- Prior art keywords
- single chain
- adenoviral
- compressors
- connector
- expressing interleukin
- Prior art date
Links
- 108010065805 Interleukin-12 Proteins 0.000 title abstract 5
- 102000013462 Interleukin-12 Human genes 0.000 title abstract 5
- 229940117681 interleukin-12 Drugs 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 102000002627 4-1BB Ligand Human genes 0.000 abstract 1
- 108010082808 4-1BB Ligand Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10248141A DE10248141B4 (de) | 2002-10-11 | 2002-10-11 | Nukleinsäuren und deren Verwendung für die Gentherapie |
| EP03757951.3A EP1556411B1 (de) | 2002-10-11 | 2003-10-10 | Adenovirale Vektoren die Einzelketten Interleukin-12 und 4-1BB Ligand exprimieren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114777T1 true CY1114777T1 (el) | 2016-12-14 |
Family
ID=32102775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101171T CY1114777T1 (el) | 2002-10-11 | 2013-12-27 | Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8067227B2 (enExample) |
| EP (1) | EP1556411B1 (enExample) |
| JP (2) | JP4615311B2 (enExample) |
| AU (1) | AU2003273983A1 (enExample) |
| CY (1) | CY1114777T1 (enExample) |
| DE (1) | DE10248141B4 (enExample) |
| DK (1) | DK1556411T3 (enExample) |
| ES (1) | ES2440951T3 (enExample) |
| PT (1) | PT1556411E (enExample) |
| SI (1) | SI1556411T1 (enExample) |
| WO (1) | WO2004035799A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069272A2 (en) * | 2003-02-05 | 2004-08-19 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
| DE102005055128B4 (de) * | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| CN102174479B (zh) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| PL3351261T3 (pl) | 2011-10-11 | 2021-12-06 | Universität Zürich | Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| SG10201913163PA (en) | 2015-12-18 | 2020-03-30 | Oncosec Medical Inc | Plasmid constructs for heterologous protein expression and methods of use |
| EP3211000B1 (en) * | 2016-02-25 | 2019-01-30 | Provecs Medical GmbH | Novel immunostimulating vector system |
| PL3458083T3 (pl) | 2016-05-18 | 2023-03-13 | Modernatx, Inc. | Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania |
| KR20240144261A (ko) | 2017-02-28 | 2024-10-02 | 사노피 | 치료적 rna |
| EP3628010A4 (en) | 2017-05-02 | 2021-02-17 | Nektar Therapeutics | IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE |
| AU2019208892B2 (en) * | 2018-01-19 | 2022-02-03 | Kolon Life Science, Inc. | Recombinant vaccinia virus and pharmaceutical composition comprising same |
| KR102907902B1 (ko) | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| US11230699B2 (en) * | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573764A (en) * | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
| WO2000041508A2 (en) | 1999-01-15 | 2000-07-20 | Mount Sinai School Of Medicine Of The City University Of New York | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
| KR20020010206A (ko) * | 2000-07-27 | 2002-02-04 | 이시우 | 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신 |
| WO2002027007A2 (en) * | 2000-09-25 | 2002-04-04 | Regents Of The University Of Michigan | Production of viral vectors |
-
2002
- 2002-10-11 DE DE10248141A patent/DE10248141B4/de not_active Expired - Fee Related
-
2003
- 2003-10-10 DK DK03757951.3T patent/DK1556411T3/da active
- 2003-10-10 SI SI200332329T patent/SI1556411T1/sl unknown
- 2003-10-10 WO PCT/EP2003/011252 patent/WO2004035799A2/de not_active Ceased
- 2003-10-10 AU AU2003273983A patent/AU2003273983A1/en not_active Abandoned
- 2003-10-10 US US10/530,706 patent/US8067227B2/en not_active Expired - Fee Related
- 2003-10-10 EP EP03757951.3A patent/EP1556411B1/de not_active Expired - Lifetime
- 2003-10-10 PT PT37579513T patent/PT1556411E/pt unknown
- 2003-10-10 JP JP2004544141A patent/JP4615311B2/ja not_active Expired - Fee Related
- 2003-10-10 ES ES03757951.3T patent/ES2440951T3/es not_active Expired - Lifetime
-
2010
- 2010-08-30 JP JP2010192832A patent/JP2011036251A/ja active Pending
-
2013
- 2013-12-27 CY CY20131101171T patent/CY1114777T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1556411A2 (de) | 2005-07-27 |
| AU2003273983A1 (en) | 2004-05-04 |
| DE10248141A1 (de) | 2004-09-02 |
| WO2004035799A2 (de) | 2004-04-29 |
| JP4615311B2 (ja) | 2011-01-19 |
| SI1556411T1 (sl) | 2014-01-31 |
| AU2003273983A8 (en) | 2004-05-04 |
| WO2004035799A3 (de) | 2004-06-10 |
| JP2006511212A (ja) | 2006-04-06 |
| US20060153805A1 (en) | 2006-07-13 |
| DE10248141B4 (de) | 2007-04-19 |
| DK1556411T3 (da) | 2014-01-20 |
| JP2011036251A (ja) | 2011-02-24 |
| ES2440951T3 (es) | 2014-01-31 |
| US8067227B2 (en) | 2011-11-29 |
| PT1556411E (pt) | 2014-01-07 |
| EP1556411B1 (de) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69819167D1 (de) | Modifizierter, das dorsalgewebe beeinflussender faktor | |
| FI961755A0 (fi) | Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi | |
| NO20004631L (no) | Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft | |
| DK1548032T3 (da) | KDR-peptider og vacciner indeholdende disse | |
| MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
| DE60222910D1 (de) | Vaccinia virus für diagnose und behandlung von tumoren | |
| CY1106783T1 (el) | Χρηση υλικου που περιεχει εικοσιδυ-πεντενοϊκο οξυ | |
| IL231502A0 (en) | Simian adenoid virus nucleic acid and amino acid sequences, vectors containing the same and methods of use | |
| DE69924826D1 (de) | Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie | |
| AU2003242305A1 (en) | Hla-a24-restricted cancer antigen peptide | |
| IL199126A (en) | Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters. | |
| WO2004035799A3 (de) | Virale vektoren und deren verwendung für die gentherapie | |
| DE69328025D1 (de) | Dorsalgewebe beeinflussender faktor und zusammensetzungen | |
| CY1105240T1 (el) | 5’ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ | |
| DK1536006T3 (da) | Cancerantigener og anvendelse deraf | |
| DK0637334T3 (da) | Peptider med en GDP-udskiftningsfaktoraktivitet, nukleinsyresekvenser, der koder for disse peptider, fremstilling og anvendelse | |
| DE60036105D1 (de) | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs | |
| DK1147212T3 (da) | T-hjælpecelle-epitoper | |
| DE69426121D1 (de) | Gen grb3-3, variante und ihre verwendungen | |
| DK0831899T3 (da) | Rekombinant koppevirus-calicivirus-præparater og anvendelser | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| ATE470717T1 (de) | Hocheffizienter, retroviraler vektor, welcher genetisch hergestellte, zelluläre, nichtkodierende sequenzen, die einen spleissakzeptor umfassen, beinhaltet | |
| DE69332375D1 (de) | Hundecoronavirus s gen und verwendung davon | |
| DE602004001047D1 (de) | Phospholipidester von Clofarabin | |
| EP2149381A3 (en) | Method of treating malignancies through induction of blood immune responses |